Your browser doesn't support javascript.
loading
The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres.
Graham, Mindy K; Xu, Beisi; Davis, Christine; Meeker, Alan K; Heaphy, Christopher M; Yegnasubramanian, Srinivasan; Dyer, Michael A; Zeineldin, Maged.
Afiliación
  • Graham MK; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Xu B; Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
  • Davis C; Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Meeker AK; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Heaphy CM; Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
  • Yegnasubramanian S; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Dyer MA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Zeineldin M; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Cancer Res Commun ; 4(6): 1533-1547, 2024 Jun 20.
Article en En | MEDLINE | ID: mdl-38837897
ABSTRACT
Acquiring a telomere maintenance mechanism is a hallmark of high-risk neuroblastoma and commonly occurs by expressing telomerase (TERT). Telomerase-negative neuroblastoma has long telomeres and utilizes the telomerase-independent alternative lengthening of telomeres (ALT) mechanism. Conversely, no discernable telomere maintenance mechanism is detected in a fraction of neuroblastoma with long telomeres. Here, we show, unlike most cancers, DNA of the TERT promoter is broadly hypomethylated in neuroblastoma. In telomerase-positive neuroblastoma cells, the hypomethylated DNA promoter is approximately 1.5 kb. The TERT locus shows active chromatin marks with low enrichment for the repressive mark, H3K27me3. MYCN, a commonly amplified oncogene in neuroblstoma, binds to the promoter and induces TERT expression. Strikingly, in neuroblastoma with long telomeres, the hypomethylated region spans the entire TERT locus, including multiple nearby genes with enrichment for the repressive H3K27me3 chromatin mark. Furthermore, subtelomeric regions showed enrichment of repressive chromatin marks in neuroblastomas with long telomeres relative to those with short telomeres. These repressive marks were even more evident at the genic loci, suggesting a telomere position effect (TPE). Inhibiting H3K27 methylation by three different EZH2 inhibitors induced the expression of TERT in cell lines with long telomeres and H3K27me3 marks in the promoter region. EZH2 inhibition facilitated MYCN binding to the TERT promoter in neuroblastoma cells with long telomeres. Taken together, these data suggest that epigenetic regulation of TERT expression differs in neuroblastoma depending on the telomere maintenance status, and H3K27 methylation is important in repressing TERT expression in neuroblastoma with long telomeres.

SIGNIFICANCE:

The epigenetic landscape of the TERT locus is unique in neuroblastoma. The DNA at the TERT locus, unlike other cancer cells and similar to normal cells, are hypomethylated in telomerase-positive neuroblastoma cells. The TERT locus is repressed by polycomb repressive complex-2 complex in neuroblastoma cells that have long telomeres and do not express TERT. Long telomeres in neuroblastoma cells are also associated with repressive chromatin states at the chromosomal termini, suggesting TPE.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Regiones Promotoras Genéticas / Telómero / Telomerasa / Neuroblastoma Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Regiones Promotoras Genéticas / Telómero / Telomerasa / Neuroblastoma Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos